Search clinical trials for: BAY1747846

Total 7 results

Bayer

Completed

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

Japan
Bayer

Completed

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

China
Bayer

Completed

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Recruiting

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Children | Contrast Enhancement in Magnetic Resonance Imaging

United States, Japan, China, Italy, Czechia, Canada, Poland, Argentina, Bulgaria, Belgium, Germany, Sweden, Hungary
Bayer

Completed

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Central Nervous System Pathology

United States, Japan, Germany, Bulgaria
Bayer

Recruiting

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (Quanti CNS)

Contrast Enhancement in Magnetic Resonance Imaging | Central Nervous System Pathology

France, Turkey, Czechia, China, Japan, United States, United Kingdom, Italy, Korea, Republic of, Germany, Bulgaria, Hungary, Argentina, Canada, Sweden
Bayer

Recruiting

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (Quanti OBR)

Contrast Enhancement in Magnetic Resonance Imaging | Non-central Nervous System Pathology

United States, Sweden, Japan, Czechia, China, Hungary, Poland, Italy, United Kingdom, Turkey, Korea, Republic of, Germany, Taiwan, France, Argentina, Bulgaria, Canada

3

Subscribe